Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Systems serology for evaluation of HIV vaccine trials.

Ackerman ME, Barouch DH, Alter G.

Immunol Rev. 2017 Jan;275(1):262-270. doi: 10.1111/imr.12503. Review.

PMID:
28133810
2.

Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.

Borrow P, Moody MA.

Immunol Rev. 2017 Jan;275(1):62-78. doi: 10.1111/imr.12504. Review.

3.

Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.

Jaworski JP, Vendrell A, Chiavenna SM.

Front Immunol. 2017 Jan 11;7:661. doi: 10.3389/fimmu.2016.00661. eCollection 2016. Review.

4.
5.

Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization.

Yamamoto H, Matano T.

Front Microbiol. 2016 Nov 2;7:1739. eCollection 2016. Review.

6.

Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.

Cheeseman HM, Olejniczak NJ, Rogers PM, Evans AB, King DF, Ziprin P, Liao HX, Haynes BF, Shattock RJ.

J Virol. 2016 Dec 16;91(1). pii: e01762-16. Print 2017 Jan 1.

7.

The differential impact of natural killer (NK) cell education via KIR2DL3 and KIR3DL1 on CCL4 secretion in the context of in-vitro HIV infection.

Lisovsky I, Isitman G, Tremblay-McLean A, Song R, DaFonseca S, Lebouchẻ B, Routy JP, Bruneau J, Bernard NF.

Clin Exp Immunol. 2016 Dec;186(3):336-346. doi: 10.1111/cei.12849. Epub 2016 Sep 9.

PMID:
27506421
8.

Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.

Gooneratne SL, Center RJ, Kent SJ, Parsons MS.

Clin Exp Immunol. 2016 Apr;184(1):101-9. doi: 10.1111/cei.12752. Epub 2016 Feb 4.

9.

HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.

Williams KL, Cortez V, Dingens AS, Gach JS, Rainwater S, Weis JF, Chen X, Spearman P, Forthal DN, Overbaugh J.

EBioMedicine. 2015 Oct;2(10):1464-77.

10.

HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions.

Rubens M, Ramamoorthy V, Saxena A, Shehadeh N, Appunni S.

J Immunol Res. 2015;2015:560347. doi: 10.1155/2015/560347. Epub 2015 Oct 22. Review.

11.

Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular Cytotoxicity.

Ruiz MJ, Ghiglione Y, Falivene J, Laufer N, Holgado MP, Socías ME, Cahn P, Sued O, Giavedoni L, Salomón H, Gherardi MM, Rodríguez AM, Turk G.

J Virol. 2016 Jan 15;90(2):670-81. doi: 10.1128/JVI.02363-15.

12.

Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein.

Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal DN, Spearman PW, Crowe JE Jr.

PLoS One. 2015 Jul 30;10(7):e0133509. doi: 10.1371/journal.pone.0133509. eCollection 2015.

13.

HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies.

Chin'ombe N, Ruhanya V.

Pan Afr Med J. 2015 Apr 20;20:386. doi: 10.11604/pamj.2015.20.386.4660. eCollection 2015. Review.

14.

Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.

Yang K, Lan J, Shepherd N, Hu N, Xing Y, Byrd D, Amet T, Jewell C, Gupta S, Kounga C, Gao J, Yu Q.

J Virol. 2015 Sep;89(18):9393-406. doi: 10.1128/JVI.01614-15. Epub 2015 Jul 1.

15.

Expression of activating receptors on natural killer cells from AIDS-related lymphoma patients.

Mercier-Bataille D, Sanchez C, Baier C, Le Treut T, Mounier N, Mokhtari S, Olive D, Baumstarck K, Sébahoun G, Besson C, Costello RT.

AIDS Res Ther. 2014 Nov 24;11:38. doi: 10.1186/1742-6405-11-38. eCollection 2014.

16.

Functions of Antibodies.

Forthal DN.

Microbiol Spectr. 2014 Aug 15;2(4):1-17. No abstract available.

17.

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC.

Cell. 2014 Aug 28;158(5):989-99. doi: 10.1016/j.cell.2014.07.043. Epub 2014 Aug 14.

18.

Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, Ackerman ME, Streeck H, Klasse PJ, Moore JP, Alter G.

Eur J Immunol. 2014 Oct;44(10):2925-37. doi: 10.1002/eji.201344305. Epub 2014 Aug 11.

19.

Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection.

Basu D, Xiao P, Ende Z, Bere A, Britt WJ, Mulenga J, Kilembe W, Allen SA, Derdeyn CA, Hunter E.

Virology. 2014 Aug;462-463:295-8. doi: 10.1016/j.virol.2014.06.016. Epub 2014 Jul 5.

20.

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA.

Clin Vaccine Immunol. 2014 Aug;21(8):1023-36. doi: 10.1128/CVI.00230-14. Epub 2014 Jun 11. Review.

Supplemental Content

Support Center